Saitoh Tsukasa, Sato Shuichi, Yazaki Tomotaka, Tobita Hiroshi, Miyake Tatsuya, Ishihara Shunji, Katsube Takashi, Kitagaki Hajime, Kinoshita Yoshikazu
Department of Gastroenterology, Matsue Red Cross Hospital, Japan.
Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan.
Intern Med. 2018 Jan 15;57(2):165-171. doi: 10.2169/internalmedicine.8801-16. Epub 2017 Oct 16.
Objective We investigated the possible factors for predicting the future progression to hepatocellular carcinoma (HCC) from hypovascular nodules detected in the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI). Methods A total of 91 hypovascular nodules detected by Gd-EOB-DTPA-MRI in 28 patients without any past history of treatment for HCC were retrospectively examined. The nodules were categorized into those with and without HCC progression, then comparisons were made to identify any factors possibly related to a progression to HCC in each case. In addition, we performed a receiver operating characteristics (ROC) analysis to determine the cut-off value for the initial nodule size for predicting HCC progression within 12 months. Results The observation period of the 28 patients was 1,172.6±95.6 (mean±standard error) days. The number of hypovascular nodules that changed to hypervascular ones was 15 (16.5%), and the cumulative incidence of hypervascular transformation was 7.1% at 12 months and 12.7% at 24 months. Of all 91 hypovascular nodules, 33 in 18 patients were diagnosed as HCC based on hypervascular transformation and/or size enlargement, while the remaining 58 did not progress to HCC. There was no significant difference regarding the background characteristics between the HCC progressed and non-progressed groups according to a multivariate analysis, or between the patients who had nodules that progressed to HCC and those with nodules that did not progress to HCC. Regarding HCC progression at 12 months, the area under the ROC (AUROC) had a level of 0.745 and showed that an initial nodule cut-off size of 9.5 mm (sensitivity, 57.9%; specificity, 87.3%) was predictive. Conclusion In patients without a past HCC treatment history, it is difficult to determine whether hypovascular nodules have a high risk of progression to HCC based on background factors alone.
目的 我们研究了钆塞酸二钠增强磁共振成像(Gd-EOB-DTPA-MRI)肝胆期检测到的乏血供结节未来进展为肝细胞癌(HCC)的可能预测因素。方法 回顾性研究28例既往无HCC治疗史患者,通过Gd-EOB-DTPA-MRI检测到的91个乏血供结节。将结节分为有和无HCC进展两组,然后进行比较以确定每种情况下可能与进展为HCC相关的因素。此外,我们进行了受试者操作特征(ROC)分析,以确定预测12个月内HCC进展的初始结节大小的临界值。结果 28例患者的观察期为1172.6±95.6(均值±标准误)天。变为富血供结节的乏血供结节数量为15个(16.5%),富血供转变的累积发生率在12个月时为7.1%,24个月时为12.7%。在所有91个乏血供结节中,18例患者的33个结节基于富血供转变和/或大小增大被诊断为HCC,其余58个未进展为HCC。根据多因素分析,HCC进展组和未进展组之间的背景特征,以及结节进展为HCC的患者和结节未进展为HCC的患者之间,均无显著差异。关于12个月时的HCC进展,ROC曲线下面积(AUROC)为0.745,表明初始结节临界大小为9.5 mm(敏感性,57.9%;特异性,87.3%)具有预测性。结论 在既往无HCC治疗史的患者中,仅根据背景因素很难确定乏血供结节进展为HCC的风险是否较高。